Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417764 | 1.00 | KIF11 (0.51) | KIF11ALDH1A1ALDH1A3CYP2A6AKR1C3 | |
| SCHEMBL1769710 | 0.84 | KIF11 (0.47) | KIF11ALDH1A1ALDH1A3CYP2A6AKR1C3 | |
| SCHEMBL17341755 | 0.82 | KIF11 (0.46) | KIF11ALDH1A1ALDH1A3CYP2A6AKR1C3 | |
| SCHEMBL19543117 | 0.82 | ALDH1A1 (0.44) | KIF11ALDH1A1ALDH1A3CYP2A6TSHR | |
| SCHEMBL26704187 | 0.81 | KIF11 (0.50) | KIF11ALDH1A1AKR1C3AKR1C2TRIM24 | |
| SCHEMBL472408 | 0.81 | KIF11 (0.56) | KIF11ALDH1A1CYP2A6AKR1C3AKR1C2 | |
| SCHEMBL6849159 | 0.79 | KIF11 (0.55) | KIF11ALDH1A1CYP2A6AKR1C3AKR1C2 | |
| SCHEMBL29061760 | 0.78 | ALDH1A1 (0.42) | KIF11ALDH1A1ALDH1A3CYP2A6TSHR | |
| SCHEMBL18727016 | 0.78 | ALDH1A1 (0.42) | KIF11ALDH1A1ALDH1A3CYP2A6TSHR | |
| SCHEMBL24028105 | 0.78 | KIF11 (0.43) | KIF11ALDH1A1ALDH1A3CYP2A6AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | claimed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | claimed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | claimed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | claimed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | claimed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240002350-A1 | PROTEIN AND LIPID THERAPEUTIC TARGETS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022108980-A1 | PROTEIN AND LIPID THERAPEUTIC TARGETS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-109496213-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-0088276-A1 | Compounds, process for their preparation and their use as pharmaceutical preparations | BAYER AG (DE) | 1983-09-14 | — | — | EP | disclosed |
| EP-0039863-A1 | 1,4-Dihydropyridines with different substituents in positions 2 and 6, processes for their preparation and their use in medicines | BAYER AG (DE) | 1981-11-18 | — | — | EP | disclosed |
| US-4248873-A | Nitro-substituted 1,4-dihydropyridines, processes for _their production and their medicinal use | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-03 | — | — | US | disclosed |
| EP-0012180-A1 | 1,4-Dihydropyridine compounds, their preparation, pharmaceutical compositions containing said compounds and preparation of these compositions | BAYER AG (DE) | 1980-06-25 | — | — | EP | disclosed |
| US-4179500-A | 1,4-Dihydropyridine-sugar derivatives, and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1979-12-18 | — | — | US | disclosed |
| EP-0002208-A1 | Nitro 1,4-dihydropyridines, medicaments containing them and their manufacture | BAYER AG (DE) | 1979-06-13 | — | — | EP | disclosed |
| EP-0001769-A1 | Sulfur-containing esters of 1,4-dihydropyridine carboxylic acids, their preparation and pharmaceutical use | BAYER AG (DE) | 1979-05-16 | — | — | EP | disclosed |
| US-4044141-A | CORONARY DILATING, SPASMOLYTIC, HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | KIF11 3898/4885ALDH1A1 3306/4885ALDH1A3 2335/4885 |
| US-20240002350-A1 | PROTEIN AND LIPID THERAPEUTIC TARGETS | PEBP1, ALOX15, ALOX15B | KIF11 4792/4885ALDH1A1 3687/4885ALDH1A3 2301/4885 |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | VIP, PEPD, NRDC | KIF11 4625/4885ALDH1A1 4861/4885ALDH1A3 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.